Clinical trial
An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-386(2) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers
NCT04987970 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-386(2) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 12, 2021
- Completion date
- November 27, 2021
- Enrollment
- 60 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hypertension and dyslipidemia